Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00WME
|
|||
| Former ID |
DCL000504
|
|||
| Drug Name |
Conatumumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Pain [ICD-11: MG30-MG3Z] | Discontinued in Phase 2 | [2] | ||
| Company |
Amgen; Takeda
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01327612) Open Label Extension Study of Conatumumab and AMG 479. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026807) | |||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
| REF 4 | Clinical pipeline report, company report or official report of Amgen (2009). | |||
| REF 5 | ClinicalTrials.gov (NCT00534027) Amgen. Report of Amgen. January 22, 2009. | |||
| REF 6 | Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.